Nerviano Medical Sciences Receives FDA “Study May Proceed” Letter for First-In-Human Phase 1 Clinical Trial under Its Investigational New Drug Application for NMS-03602173, a Dual IDH1/2 Inhibitor, in Advanced Solid Tumors
Nerviano, 22 October 2021 Nerviano Medical Sciences (NMS Srl,) a member of NMS Group and a pharmaceutical company developing innovative new chemical entities (NCE) for the treatment of cancers, today announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate NMS-03602173, a second-generation oral inhibitor of […]
NMS-173, a potent, covalent second generation IDH1/IDH2 inhibitor
Magnaghi P., Casuscelli F., Ardini E., Parazzoli A., Troiani S., Valsasina B., Texido G., Casale E., Avanzi N., Orsini P., Nuvoloni S., Salom B., Lombardi Borgia A., Salsi E., Saturno G., Re Depaolini S., Stellato C., Montagnoli A., Galvani A. and Isacchi A. 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; October 26 – […]
Development of an Effective Tumor-Targeted Contrast Agent for Magnetic Resonance Imaging Based on Mn/H-Ferritin Nanocomplexes
Tullio C, Salvioni L, Bellini M, Degrassi A, Fiandra L, D’Arienzo M, Garbujo S, Rotem R, Testa F, Prosperi D, Colombo M ACS Appl Bio Mater (2021), 15, 4(11), 7800-7810
A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas
Vannata B, Vanazzi A, Negri M, Liptrott SJ, Bartosek A , Miani M , Di Sanzo A, Cavalli F, Zucca E, Stathis A Hematol Oncol (2021), 39(1), 60-65.
Development of an Effective Tumor-Targeted Contrast Agent for Magnetic Resonance Imaging Based on Mn/H-Ferritin Nanocomplexes
Tullio C, Salvioni L, Bellini M, Degrassi A, Fiandra L, D’Arienzo M, Garbujo S, Rotem R, Testa F, Prosperi D, Colombo M ACS Appl Bio Mater (2021), 15, 4(11), 7800-7810
Pharma Tech Outlook Names NMS Group a Top Drug Discovery and Development Solution Provider in Europe 2021
NMS Group is proud to be named by Pharma Tech Outlook as Top drug discovery and development solution providers in Europe for 2021 and featured in the cover of this special issue. The annual list showcases companies that are providing cutting-edge drug discovery and development tech solutions and services. Determined by a panel of experts […]
Entrectinib, the kinase inhibitor drug initially discovered and developed by Nerviano Medical Sciences approved by AIFA in two oncology indications
Entrectinib, the kinase inhibitor drug that was initially discovered and developed by Nerviano Medical Sciences (a member of NMS Group) and that is now marketed by Roche and partners, has received approval for marketing and reimbursement from the Italian drug agency AIFA in two oncology indications: lung cancer ROS1 kinase fusion positive, and any solid […]
CPhI Worldwide
Where: Fiera Milano, Milan, Italy When: 9 November – 11 November 2021 CPhI Worldwide 2021 has established itself as the flagship event for the pharmaceutical industry. The upcoming edition of the expo will be staged from 9th to 11th of November at Fiera Milano. The organizers expect an even bigger gathering of professionals and […]
Accelera and BiomimX: Commercial agreement
Nerviano, 30 June 2021 Accelera Srl and BiomimX® Srl have signed a non-exclusive commercial agreement following an intense scientific collaboration aimed at introducing and applying new technological solutions to the drug discovery process. The commercial agreement between the Companies determines that Accelera proposes within its commercial offer BiomimX®’s technological solutions: uHeart and uKnee. uHeart, is […]
The Coup-TFII orphan nuclear receptor is an activator of the γ-globin gene
Fugazza C, Barbarani G, Elangovan S, Marini MG, Giolitto S, Font-Monclus I, Marongiu MF, Manunza L, Strouboulis J, Cantù C, Gasparri F, Barabino SML, Nakamura Y, Ottolenghi S, Moi P, Ronchi AE Haematologica (2021), 106(2), 474-482
